Q4 EPS Estimates for Core Laboratories Cut by Zacks Research

Key Points

• Zacks Research has revised down its Q4 2026 earnings per share estimate for Core Laboratories from $0.26 to $0.24, while the full-year earnings estimate remains at $0.96 per share.
• The company recently declared a quarterly dividend of $0.01 per share, reflecting an annualized dividend of $0.04 and a yield of 0.4%.
• Core Laboratories' stock price declined 0.7% to $10.20, with recent trading activity showing a market cap of $478.28 million and a P/E ratio of 16.45.

Core Laboratories Inc. (NYSE:CLB - Free Report) - Equities research analysts at Zacks Research lowered their Q4 2026 earnings per share (EPS) estimates for Core Laboratories in a research note issued to investors on Friday, August 8th. Zacks Research analyst R. Department now expects that the oil and gas company will post earnings of $0.24 per share for the quarter, down from their previous forecast of $0.26. The consensus estimate for Core Laboratories' current full-year earnings is $0.96 per share. Zacks Research also issued estimates for Core Laboratories' Q2 2027 earnings at $0.27 EPS.

Core Laboratories (NYSE:CLB - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The oil and gas company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.01. Core Laboratories had a return on equity of 14.15% and a net margin of 5.73%. The business had revenue of $130.16 million for the quarter, compared to analysts' expectations of $129.19 million. During the same quarter in the previous year, the firm earned $0.22 earnings per share. The business's revenue was down .3% on a year-over-year basis.

CLB has been the topic of several other research reports. Wall Street Zen raised Core Laboratories from a "sell" rating to a "hold" rating in a research report on Saturday, July 26th. Citigroup cut their price objective on Core Laboratories from $16.00 to $13.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Finally, Stifel Nicolaus cut their price objective on Core Laboratories from $13.00 to $12.00 and set a "hold" rating on the stock in a research report on Wednesday, July 16th.

Core Laboratories Stock Down 0.7%

CLB stock opened at $10.20 on Monday. The stock's fifty day simple moving average is $11.78 and its two-hundred day simple moving average is $13.24. The company has a current ratio of 2.27, a quick ratio of 1.70 and a debt-to-equity ratio of 0.47. Core Laboratories has a 1-year low of $10.14 and a 1-year high of $21.83. The stock has a market cap of $478.28 million, a P/E ratio of 16.45, a P/E/G ratio of 3.11 and a beta of 1.41.

Core Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 25th. Stockholders of record on Monday, August 4th will be given a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, August 4th. Core Laboratories's dividend payout ratio is currently 6.45%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Ridgewood Investments LLC lifted its position in shares of Core Laboratories by 2.7% during the 1st quarter. Ridgewood Investments LLC now owns 33,486 shares of the oil and gas company's stock valued at $502,000 after buying an additional 874 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Core Laboratories by 3.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,723 shares of the oil and gas company's stock valued at $463,000 after purchasing an additional 960 shares during the period. Mackenzie Financial Corp raised its stake in shares of Core Laboratories by 5.0% during the 1st quarter. Mackenzie Financial Corp now owns 24,556 shares of the oil and gas company's stock valued at $368,000 after purchasing an additional 1,170 shares during the period. Assetmark Inc. raised its stake in shares of Core Laboratories by 92.5% during the 1st quarter. Assetmark Inc. now owns 2,887 shares of the oil and gas company's stock valued at $43,000 after purchasing an additional 1,387 shares during the period. Finally, Captrust Financial Advisors raised its stake in shares of Core Laboratories by 3.2% during the 4th quarter. Captrust Financial Advisors now owns 55,527 shares of the oil and gas company's stock valued at $961,000 after purchasing an additional 1,728 shares during the period. Hedge funds and other institutional investors own 97.81% of the company's stock.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.